## Edgar Filing: MYLAN LABORATORIES INC - Form 8-K

## MYLAN LABORATORIES INC Form 8-K July 07, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 7, 2005 (July 6, 2005)

Pennsylvania 1-9114 25-1211621 (State or other jurisdiction of Incorporation) Number) Identification No.)

1500 Corporate Drive Canonsburg, PA 15317 (Address of principal executive offices)

(724) 514-1800 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
- Item 5.02 Departure of Directors or Principal Officers; Election of
  Directors; Appointment of Principal Officers.
- (b) Effective July 6, 2005, Patricia A. Sunseri and Stuart A. Williams resigned as directors of Mylan Laboratories Inc.

## Edgar Filing: MYLAN LABORATORIES INC - Form 8-K

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

Date: July 7, 2005 By: /s/ Edward J. Borkowski

\_\_\_\_\_

Edward J. Borkowski Chief Financial Officer